Trial Information - Phase III
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001
Protocol ID: D361BC00001
Sponsor: AstraZeneca plc
Status: STAR Trial
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
